These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 6214992

  • 1. Clinical evaluation of the therapeutic efficacy and tolerability of piperacillin.
    Lutz B, Mogabgab W, Holmes B, Pollock B, Beville R.
    Antimicrob Agents Chemother; 1982 Jul; 22(1):10-4. PubMed ID: 6214992
    [Abstract] [Full Text] [Related]

  • 2. Preliminary report comparing piperacillin and carbenicillin for complicated urinary tract infections.
    Swarifi R, Lee M, Ojeda L, Tabib M.
    J Urol; 1982 Oct; 128(4):755-8. PubMed ID: 6216344
    [Abstract] [Full Text] [Related]

  • 3. Piperacillin v Carbenicillin in the therapy for serious infections.
    Marier RL, Sanders CV, Faro S, Janney A, Williams WW, Derks F, Aldridge KE.
    Arch Intern Med; 1982 Oct 25; 142(11):2000-5. PubMed ID: 6215008
    [Abstract] [Full Text] [Related]

  • 4. Piperacillin sodium: antibacterial spectrum, pharmacokinetics, clinical efficacy, and adverse reactions.
    Fortner CL, Finley RS, Schimpff SC.
    Pharmacotherapy; 1982 Oct 25; 2(6):287-99. PubMed ID: 6220262
    [Abstract] [Full Text] [Related]

  • 5. Clinical evaluation of piperacillin therapy for infection.
    Pancoast S, Prince AS, Francke EL, Neu HC.
    Arch Intern Med; 1981 Oct 25; 141(11):1447-50. PubMed ID: 6456708
    [Abstract] [Full Text] [Related]

  • 6. Timentin versus piperacillin in the treatment of hospitalized patients with urinary tract infections.
    Cox CE.
    J Antimicrob Chemother; 1986 May 25; 17 Suppl C():93-6. PubMed ID: 3636340
    [Abstract] [Full Text] [Related]

  • 7. Susceptibility patterns of bacteria following therapy with piperacillin.
    Marier RL, Marinaccio AT, Sanders CV, Aldridge KE, Mitchell JW.
    J Antimicrob Chemother; 1982 Feb 25; 9 Suppl B():85-91. PubMed ID: 6460737
    [No Abstract] [Full Text] [Related]

  • 8. Clinical trial of piperacillin with acquisition of resistance by Pseudomonas and clinical relapse.
    Simon GL, Snydman DR, Tally FP, Gorbach SL.
    Antimicrob Agents Chemother; 1980 Jul 25; 18(1):167-70. PubMed ID: 6448020
    [Abstract] [Full Text] [Related]

  • 9. Piperacillin and gentamicin v carbenicillin and gentamicin for treatment of serious gram-negative infections.
    Kohler RB, Foerster LA, Wheat LJ, Williams JM, Reynolds J, Norton J.
    Arch Intern Med; 1982 Jul 25; 142(7):1335-7. PubMed ID: 6212035
    [Abstract] [Full Text] [Related]

  • 10. Clinical evaluation of piperacillin.
    Thadepalli H, Rao B, White D, Bach VT.
    Chemotherapy; 1980 Jul 25; 26(5):377-83. PubMed ID: 6446449
    [Abstract] [Full Text] [Related]

  • 11. Piperacillin: a review of clinical experience.
    Gooding PG, Clark BJ, Sathe SS.
    J Antimicrob Chemother; 1982 Feb 25; 9 Suppl B():93-9. PubMed ID: 6460738
    [No Abstract] [Full Text] [Related]

  • 12. Comparative efficacy of piperacillin versus carbenicillin for complicated urinary tract infections.
    Sharifi R, Lee M, Ojeda L.
    Urol Int; 1984 Feb 25; 39(6):345-51. PubMed ID: 6395464
    [Abstract] [Full Text] [Related]

  • 13. Piperacillin therapy for serious bacterial infections.
    Winston DJ, Murphy W, Young LS, Hewitt WL.
    Am J Med; 1980 Aug 25; 69(2):255-61. PubMed ID: 6447455
    [No Abstract] [Full Text] [Related]

  • 14. Azlocillin, mezlocillin, and piperacillin: new broad-spectrum penicillins.
    Eliopoulos GM, Moellering RC.
    Ann Intern Med; 1982 Nov 25; 97(5):755-60. PubMed ID: 6215872
    [Abstract] [Full Text] [Related]

  • 15. Piperacillin against clinical isolates: antimicrobial profile and clinical role.
    McAllister TA.
    J Antimicrob Chemother; 1982 Feb 25; 9 Suppl B():75-84. PubMed ID: 6460736
    [No Abstract] [Full Text] [Related]

  • 16. Timentin versus piperacillin in the therapy of serious urinary tract infections.
    File TM, Tan JS, Salstrom SJ, Johnson L.
    Am J Med; 1985 Nov 29; 79(5B):91-5. PubMed ID: 4073102
    [Abstract] [Full Text] [Related]

  • 17. Susceptibility of the anaerobic bacteria, group D streptococci, Enterobacteriaceae, and Pseudomonas to semisynthetic penicillins: carbenicillin, piperacillin, and ticarcillin.
    Monif GR, Clark PR, Shuster JJ, Baer H.
    Antimicrob Agents Chemother; 1978 Nov 29; 14(5):643-9. PubMed ID: 103491
    [Abstract] [Full Text] [Related]

  • 18. Piperacillin (T-1220), a new semisynthetic penicillin. II. In vitro antimicrobial activity and synergy comparison with carbenicillin and gentamicin.
    Jones RN, Packer RR, Barry AL, Badal RE, Thornsberry C, Baker C.
    J Antibiot (Tokyo); 1979 Jan 29; 32(1):29-35. PubMed ID: 761991
    [Abstract] [Full Text] [Related]

  • 19. [Sulbactam in combination with mezlocillin, piperacillin or cefotaxime. Clinical and bacteriological results in the treatment of severe bacterial infections].
    Manncke K, Springsklee M, Heizmann WR, Sonntag HG.
    Med Klin (Munich); 1991 Sep 15; 86(9):454-60. PubMed ID: 1943983
    [Abstract] [Full Text] [Related]

  • 20. Comparative efficacy and tolerance study of azlocillin and carbenicillin in patients with cystic fibrosis: a double blind study.
    Huang NN, Palmer J, Keith H, Schidlow D, Braverman S, Goldberg M.
    J Antimicrob Chemother; 1983 May 15; 11 Suppl B():205-14. PubMed ID: 6352603
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.